WebSep 2, 2024 · Dyne Therapeutics (NASDAQ:DYN) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is advancing a pipeline of drug treatment ...
RNA therapeutics on the rise - Nature
WebMar 20, 2024 · Dyne Therapeutics, Inc today announced three poster presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 19-22, 2024, in Dallas, TX, and virtually. ... Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne ... WebOct 25, 2012 · Dr. Jocelyn Patricia Serrano - Ashburn VA, Family Practice at 44095 Pipeline Plz Suite 370. Phone: (703) 858-3140. View info, ratings, reviews, specialties, education … officer anderson this american life
Dyne Therapeutics Announces $115 Million Financing to Advance Pipeline …
WebDec 17, 2024 · Trials with more than two dozen novel RNA therapeutics or vaccines are expected to start in 2024, as per a GlobalData analysis. Given the success of the Covid-19 vaccines, a number of these planned studies deal with the authorized candidates in different settings, or newer mRNA vaccines for other infectious diseases like influenza, RSV and ... WebDyne Therapeutics is a biotechnology company which offers targeted therapies for patients with cardiac diseases, and serious and smooth muscle diseases. The Company … WebJun 2, 2024 · - Co-founder Romesh Subramanian, Ph.D., stepping down as chief scientific officer and will serve as an advisor after leading successful R&D and pipeline-building efforts - - Oxana Beskrovnaya, Ph.D., appointed CSO - WALTHAM, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. officer and gentleman opening scene